Mitsubishi Tanabe Pharma America

Mitsubishi Tanabe Pharma America (MTPA) is a company helping people who are struggling with serious and debilitating diseases. It focuses on scientific discovery in many areas including amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Employee Rating

4.1
TypeSubsidiary
HQJersey City, NJ, US
Founded2016
Websitemt-pharma-america.com
Cybersecurity ratingAMore
Mitsubishi Tanabe Pharma America was founded in 2016 and is headquartered in Jersey City, NJ, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Mitsubishi Tanabe Pharma America

Kevin O'Brien

Kevin O'Brien

Vice President, Market Access
Gustavo A. Suarez

Gustavo A. Suarez

Vice President, Medical Affairs
Joseph Scalia

Joseph Scalia

Vice President, Sales & Marketing
Sam Shum

Sam Shum

Vice President, Operations & Strategy
Tatyana Baranovsky

Tatyana Baranovsky

Associate Director, Trade Channel Strategy in Market Access
Nancy Bayerlein

Nancy Bayerlein

Director of Patient Engagement and Support
Show more

Mitsubishi Tanabe Pharma America Office Locations

Mitsubishi Tanabe Pharma America has an office in Jersey City
Jersey City, NJ, US (HQ)
525 Washington Blvd #400
Show all (1)

Mitsubishi Tanabe Pharma America Financials and Metrics

Summary Metrics

Founding Date

2016

Mitsubishi Tanabe Pharma America Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Mitsubishi Tanabe Pharma America Online and Social Media Presence

Embed Graph

Mitsubishi Tanabe Pharma America News and Updates

Mitsubishi Tanabe Pharma America Announces Presentations at 146th Annual Meeting of the American Neurological Association

JERSEY CITY, N.J., Oct. 15, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two abstracts on amyotrophic lateral sclerosis (ALS) will be presented during the 146th Annual Meeting of the American Neurological Association (ANA2021), being held...

Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities

JERSEY CITY, N.J., March 17, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the ability of people with amyotrophic lateral sclerosis (ALS) to independently conduct activities...

Mitsubishi Tanabe Pharma America Blogs

Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND

The post Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND appeared first on Mitsubishi Tanabe Pharma America.

Mitsubishi Tanabe Pharma America Highlights ALS Research at Northeast Amyotrophic Lateral Sclerosis 20th Annual Meeting

The post Mitsubishi Tanabe Pharma America Highlights ALS Research at Northeast Amyotrophic Lateral Sclerosis 20th Annual Meeting appeared first on Mitsubishi Tanabe Pharma America.

Mitsubishi Tanabe Pharma America Celebrates Fourth Anniversary of U.S. Availability of RADICAVA® (edaravone) for Treatment of ALS

The post Mitsubishi Tanabe Pharma America Celebrates Fourth Anniversary of U.S. Availability of RADICAVA® (edaravone) for Treatment of ALS appeared first on Mitsubishi Tanabe Pharma America.

Mitsubishi Tanabe Pharma America and Target ALS Announce Call for Nominations for First Annual Rebecca Luker Courage Award

The post Mitsubishi Tanabe Pharma America and Target ALS Announce Call for Nominations for First Annual Rebecca Luker Courage Award appeared first on Mitsubishi Tanabe Pharma America.

Mitsubishi Tanabe Pharma America Announces EXSERVAN™(riluzole) is Now Available in the U.S. for the Treatment of ALS

The post Mitsubishi Tanabe Pharma America Announces EXSERVAN<sup>™</sup><br />(riluzole) is Now Available in the U.S. for the Treatment of ALS appeared first on Mitsubishi Tanabe Pharma America.

MTPA Announces PANTHERx® Selected as Exclusive Provider of U.S. Specialty Pharmacy Services for EXSERVAN™ (riluzole) Oral Film

The post MTPA Announces PANTHERx<sup>®</sup> Selected as Exclusive Provider of U.S. Specialty Pharmacy Services for EXSERVAN™ (riluzole) Oral Film appeared first on Mitsubishi Tanabe Pharma America.
Show more

Mitsubishi Tanabe Pharma America Frequently Asked Questions

  • When was Mitsubishi Tanabe Pharma America founded?

    Mitsubishi Tanabe Pharma America was founded in 2016.

  • Who are Mitsubishi Tanabe Pharma America key executives?

    Mitsubishi Tanabe Pharma America's key executives are Kevin O'Brien, Gustavo A. Suarez and Joseph Scalia.

  • How many employees does Mitsubishi Tanabe Pharma America have?

    Mitsubishi Tanabe Pharma America has 178 employees.

  • Who are Mitsubishi Tanabe Pharma America competitors?

    Competitors of Mitsubishi Tanabe Pharma America include Meridian Clinical Research, Arbro and ICTA.

  • Where is Mitsubishi Tanabe Pharma America headquarters?

    Mitsubishi Tanabe Pharma America headquarters is located at 525 Washington Blvd #400, Jersey City.

  • Where are Mitsubishi Tanabe Pharma America offices?

    Mitsubishi Tanabe Pharma America has an office in Jersey City.

  • How many offices does Mitsubishi Tanabe Pharma America have?

    Mitsubishi Tanabe Pharma America has 1 office.